BOISE, Idaho, May 27, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) announced today that it will hold its fiscal third quarter earnings conference call on Wednesday, June 24, 2026, at 2:30 p.m. Mountain time. The call will be webcast live at http://investors.micron.com/. Webcast replays of presentations can be accessed from Micron’s Investor Relations website for approximately one ...
July arabica coffee (KCN26) on Wednesday closed down -4.15 (-1.51%), and July ICE robusta coffee (RMN26) closed down -47 (-1.34%). Coffee prices fell from 1.5-week highs on Wednesday and settled lower after weakness in the Brazilian real sparked long liquidation in coffee futures. The real (^USDBRL) fell to a 1-week low on Wednesday, encouraging export sales from Brazil's coffee producers. Don’t M...
July arabica coffee (KCN26) on Wednesday closed down -4.15 (-1.51%), and July ICE robusta coffee (RMN26) closed down -47 (-1.34%). Coffee prices fell from 1.5-week highs on Wednesday and settled lower after weakness in the Brazilian real sparked long liquidation in coffee futures. The real (^USDBRL) fell to a 1-week low on Wednesday, encouraging export sales from Brazil's coffee producers. Don’t Miss a Day: Coffee prices on Wednesday initially climbed to 1.5-week highs on global weather risks. Robusta rose sharply amid dry weather in Vietnam, which is raising concerns about the country's robusta coffee crop. Weather forecaster Vaisala said recent showers in Vietnam's Central Highlands, the country's main growing region, have been spotty, and more rain is needed to aid cherry growth. Concerns that an El Niño weather pattern could hurt Brazil's coffee crop next year are also supportive for prices. Coffee trader Commercial said the El Niño weather pattern may delay rains in Brazil this September and October, when tree flowering normally occurs, hurting Brazil's 2026/27 coffee crop. The US National Oceanic and Atmospheric Administration (NOAA) estimates a 82% probability that El Niño conditions will emerge between May and July and persist through the end of the year, with a 67% chance of a "Super El Niño." Coffee prices have ratcheted lower over the past month, with arabica falling to a 1.5-year nearest-futures low last Tuesday, amid an improved global supply outlook. On May 7, the Coffee Trading Academy projected Brazil's 2026/27 coffee harvest will increase by 12% y/y to 71.4 million bags. On March 19, Marex Group Plc projected a record 2026/27 Brazilian coffee crop of 75.9 million bags, surpassing Sucafina's forecast of 75.4 million bags (+15.5% y/y). On March 12, StoneX raised its Brazil 2026/27 coffee production estimate to a record 75.3 million bags, up from a November estimate of 70.7 million bags. Meanwhile, StoneX projected the 2026 global coffee surplus will e...
The following companies are expected to report earnings prior to market open on 05/28/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Royal Bank Of Canada (RY)is reporting for the quarter ending April 30, 2026. The bank (foreign) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $2.81. This value represents a 27.73% increa...
The following companies are expected to report earnings prior to market open on 05/28/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Royal Bank Of Canada (RY)is reporting for the quarter ending April 30, 2026. The bank (foreign) company's consensus earnings per share forecast from the 4 analysts that follow the stock is $2.81. This value represents a 27.73% increase compared to the same quarter last year. RY missed the consensus earnings per share in the 2nd calendar quarter of 2025 by -2.22%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for RY is 16.48 vs. an industry ratio of 11.40, implying that they will have a higher earnings growth than their competitors in the same industry. Toronto Dominion Bank (TD)is reporting for the quarter ending April 30, 2026. The bank (foreign) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.63. This value represents a 17.27% increase compared to the same quarter last year. In the past year TD has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 7.98%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for TD is 16.34 vs. an industry ratio of 11.40, implying that they will have a higher earnings growth than their competitors in the same industry. Canadian Imperial Bank of Commerce (CM)is reporting for the quarter ending April 30, 2026. The bank (foreign) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.78. This value represents a 23.61% increase compared to the same quarter last year. In the past year CM has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 14.37%. Zacks Investment Research reports that the 2026 Price to Earnings ratio for CM is 15.48 vs. an industry ratio of 11.40, implying that they will have a higher earni...
Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit. However, it lost its lead to Eli Lilly's (LLY +1.94%) Zepbound, which was approved more than two years after Wegovy. Novo Nordisk is still trying to regain its crown, and the Denmark-based pharmaceutical giant seems to be outpacing Eli Lilly in the oral anti-obesity niche. Coul...
Novo Nordisk (NVO +0.89%) pioneered weight loss medicines with Wegovy, an anti-obesity therapy that quickly became a hit. However, it lost its lead to Eli Lilly's (LLY +1.94%) Zepbound, which was approved more than two years after Wegovy. Novo Nordisk is still trying to regain its crown, and the Denmark-based pharmaceutical giant seems to be outpacing Eli Lilly in the oral anti-obesity niche. Could this become a problem for Eli Lilly? More than a first-mover advantage Novo Nordisk launched oral Wegovy in January, while Eli Lilly's competitor, Foundayo, hit the shelves in April. So, it's not that surprising that the former has more prescriptions so far. Both are attracting a significant number of patients who are brand-new to the GLP-1 class. Eli Lilly's management reports that so far, those represent 80% of patients, whereas that number stood at 36% for oral Wegovy. However, according to some data, Foundayo is trailing oral Wegovy in terms of prescription volumes at similar points after their respective launches. This may be because oral Wegovy was first-in-class, but there are likely other reasons as well. For instance, Novo Nordisk's pill seems more effective than its competitor's. It's always hard to compare across clinical trials, but oral Wegovy's 13.6% mean weight loss (at the highest dose) in 64-weeks in a phase 3 study looks a lot better than Foundayo's 11.1% mean weight loss in 72 weeks. True, the latter does have some advantage. It can be administered without restrictions on food or water intake, unlike its competitor. Foundayo should also receive label expansions, notably in diabetes. These factors could eventually allow it to catch up to oral Wegovy. But for now, Novo Nordisk seems to have finally found a way to one-up Eli Lilly. Novo Nordisk also recently received approval for oral Wegovy in the European Union, which will significantly expand its addressable market. Expand NYSE : NVO Novo Nordisk Today's Change ( 0.89 %) $ 0.40 Current Price $ 44.59 Key...
In a splashy move that signals that Taiwan remains irreplaceable to the AI industry's short-term and long-term goals, Nvidia CEO Jensen Huang announced Wednesday that his chip company will invest $150 billion a year to make sure Taiwan remains at the "epicenter" of the "AI revolution." "This is where the chips come, packaging comes, this is where the systems are made, this is where AI supercompute...
In a splashy move that signals that Taiwan remains irreplaceable to the AI industry's short-term and long-term goals, Nvidia CEO Jensen Huang announced Wednesday that his chip company will invest $150 billion a year to make sure Taiwan remains at the "epicenter" of the "AI revolution." "This is where the chips come, packaging comes, this is where the systems are made, this is where AI supercomputers were created," Huang said. "The number of partners we work with here in Taiwan, incredible." As Reuters reported , the substantial investments will be used to create a new Taiwan headquarters for Nvidia, which Huang expects will drive so much AI innovation that the partnership will cement Taiwan as "the world's tech manufacturing hub for a long time." That ambitious project will be operational by 2030, Nvidia anticipates, after breaking ground this year. Read full article Comments
Among the many Chinese AI companies and laboratories vying for market share and attention (no pun intended) on the global marketplace, MiniMax stands out for its commitment to providing frontier-level intelligence across a range of modalities, including text, coding, and video (through its Hailuo model series) — often under permissive, enterprise-friendly, standard open source licenses. Now, MiniM...
Among the many Chinese AI companies and laboratories vying for market share and attention (no pun intended) on the global marketplace, MiniMax stands out for its commitment to providing frontier-level intelligence across a range of modalities, including text, coding, and video (through its Hailuo model series) — often under permissive, enterprise-friendly, standard open source licenses. Now, MiniMax is again raising the eyebrows of AI power users and developers around the world by releasing a new, in-depth technical report on the making of its popular M2 series of language models ( M2 , M2.5 , and M2.7 ) shedding light on its numerous engineering innovations and clever approaches — while the company and its leaders also teased a whole new sparse attention approach for its upcoming MiniMax M3 series of models , which it says yields up to 15.6 times faster decoding (or LLM response) speed at long contexts (a million tokens) by adopting a custom sub-quadratic framework. In so doing, MiniMax has designed M3 to make ultra-long-context AI agent deployment economically viable. The M2 report is noteworthy for any enterprise working with AI models, and especially those looking to fine-tune and train their own in-house. After all, MiniMax's M2 series models often achieved top benchmarks in the world for open source AI performance when they were released. While the title has since been eclipsed by several other Chinese labs including DeepSeek and Xiaomi, MiniMax's new report offers a blueprint that can be used to improve AI model and agent performance by enterprises around the world. As Adina Yakup of Hugging Face observed on X , "Beyond the benchmarks, they’ve done some really solid work on MoE efficiency and agent oriented design. Excited to see where M3 goes next!" The attention dilemma The core technical architecture of the M2 series relies on a sparse Mixture-of-Experts (MoE) decoder-only Transformer layout used by numerous other state-of-the-art LLMs. The foundational ba...
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Interdigital Inc (Symbol: IDCC) presently has an excellent rank, in the top 25% of the coverage universe, which suggests i...
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Interdigital Inc (Symbol: IDCC) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making Interdigital Inc an even more interesting and timely stock to look at, is the fact that in trading on Wednesday, shares of IDCC entered into oversold territory, changing hands as low as $252.37 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Interdigital Inc, the RSI reading has hit 27.5 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 53.1. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, IDCC's recent annualized dividend of 2.8/share (currently paid in quarterly installments) works out to an annual yield of 1.06% based upon the recent $263.36 share price. A bullish investor could look at IDCC's 27.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on IDCC is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue. Click here to find out what 9 other oversold dividend stocks you need to...
In trading on Wednesday, shares of the American Century Diversified Municipal Bond ETF (Symbol: TAXF) crossed above their 200 day moving average of $50.33, changing hands as high as $50.42 per share. American Century Diversified Municipal Bond shares are currently trading up about 0.2% on the day. The chart below shows the one year performance of TAXF shares, versus its 200 day moving average: Loo...
In trading on Wednesday, shares of the American Century Diversified Municipal Bond ETF (Symbol: TAXF) crossed above their 200 day moving average of $50.33, changing hands as high as $50.42 per share. American Century Diversified Municipal Bond shares are currently trading up about 0.2% on the day. The chart below shows the one year performance of TAXF shares, versus its 200 day moving average: Looking at the chart above, TAXF's low point in its 52 week range is $48.34 per share, with $51.42 as the 52 week high point — that compares with a last trade of $50.40. Click here to find out which 9 other ETFs recently crossed above their 200 day moving average » Further TAXF Research: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Wednesday, shares of American Financial Group Inc (Symbol: AFG) crossed below their 200 day moving average of $134.03, changing hands as low as $133.54 per share. American Financial Group Inc shares are currently trading down about 1.6% on the day. The chart below shows the one year performance of AFG shares, versus its 200 day moving average: Looking at the chart above, AFG's low po...
In trading on Wednesday, shares of American Financial Group Inc (Symbol: AFG) crossed below their 200 day moving average of $134.03, changing hands as low as $133.54 per share. American Financial Group Inc shares are currently trading down about 1.6% on the day. The chart below shows the one year performance of AFG shares, versus its 200 day moving average: Looking at the chart above, AFG's low point in its 52 week range is $121.44 per share, with $150.02 as the 52 week high point — that compares with a last trade of $133.37. Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Further AFG Research: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In trading on Wednesday, shares of BlackRock MuniYield Quality Fund III (Symbol: MYI) crossed above their 200 day moving average of $10.92, changing hands as high as $10.97 per share. BlackRock MuniYield Quality Fund III shares are currently trading up about 1% on the day. The chart below shows the one year performance of MYI shares, versus its 200 day moving average: Looking at the chart above, M...
In trading on Wednesday, shares of BlackRock MuniYield Quality Fund III (Symbol: MYI) crossed above their 200 day moving average of $10.92, changing hands as high as $10.97 per share. BlackRock MuniYield Quality Fund III shares are currently trading up about 1% on the day. The chart below shows the one year performance of MYI shares, versus its 200 day moving average: Looking at the chart above, MYI's low point in its 52 week range is $10.20 per share, with $11.46 as the 52 week high point — that compares with a last trade of $10.93. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Further MYI Research: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image source: The Motley Fool. Monday, May 18, 2026 at 8:00 a.m. ET Call participants Chief Executive Officer — Faheem Hasnain Chief Financial Officer — Bryan Giraudo Chief Regulatory Officer — Caryn Peterson Chief Development Officer — Robert Roscigno Chief Commercial Officer — Bob Smith Chief Medical Officer — Jean-Marie Bruey Need a quote from a Motley Fool analyst? Email [email protected] Take...
Image source: The Motley Fool. Monday, May 18, 2026 at 8:00 a.m. ET Call participants Chief Executive Officer — Faheem Hasnain Chief Financial Officer — Bryan Giraudo Chief Regulatory Officer — Caryn Peterson Chief Development Officer — Robert Roscigno Chief Commercial Officer — Bob Smith Chief Medical Officer — Jean-Marie Bruey Need a quote from a Motley Fool analyst? Email [email protected] Takeaways PROSERA top-line results -- Phase III PROSERA showed a placebo-adjusted improvement in 6-minute walk distance of 13.3 meters (28.2 meters on seralutinib vs. 13.5 meters on placebo; p=0.032), meeting statistical significance at the 0.05 level but not the prespecified 0.025 alpha threshold. -- Phase III PROSERA showed a placebo-adjusted improvement in 6-minute walk distance of 13.3 meters (28.2 meters on seralutinib vs. 13.5 meters on placebo; p=0.032), meeting statistical significance at the 0.05 level but not the prespecified 0.025 alpha threshold. Secondary endpoints -- All four key secondary endpoints in PROSERA favored seralutinib over placebo, with a more pronounced effect in a risk-enriched subgroup. -- All four key secondary endpoints in PROSERA favored seralutinib over placebo, with a more pronounced effect in a risk-enriched subgroup. CT FRI substudy -- The substudy enrolled 162 patients (125 evaluable for paired scans); results showed statistically significant treatment effects across arterial, venous, and fibrosis-like parenchymal parameters. -- The substudy enrolled 162 patients (125 evaluable for paired scans); results showed statistically significant treatment effects across arterial, venous, and fibrosis-like parenchymal parameters. Clinical correlations -- CT FRI imaging parameters correlated with improvements in 6-minute walk distance, NT-proBNP, and REVEAL Lite 2 clinical measures. -- CT FRI imaging parameters correlated with improvements in 6-minute walk distance, NT-proBNP, and REVEAL Lite 2 clinical measures. Regulatory path -- Gossamer Bio GOSS 2....
Image source: The Motley Fool. Monday, May 18, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Jonathan Javitt Chief Financial Officer — Michael Abrams Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Debt Position -- NRx Pharmaceuticals NRXP 0.70% ) -- NRx Pharmaceuticals Cash and Liquidity -- The company reported $6.7 million in cash and cash equivalents a...
Image source: The Motley Fool. Monday, May 18, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Jonathan Javitt Chief Financial Officer — Michael Abrams Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Debt Position -- NRx Pharmaceuticals NRXP 0.70% ) -- NRx Pharmaceuticals Cash and Liquidity -- The company reported $6.7 million in cash and cash equivalents as of March 31, 2026, and subsequently raised $7 million from stock sales, with management stating "sufficient cash for our immediate operating needs." -- The company reported $6.7 million in cash and cash equivalents as of March 31, 2026, and subsequently raised $7 million from stock sales, with management stating "sufficient cash for our immediate operating needs." Net Loss -- Net loss was $1.4 million or $0.04 per share, a 74% decrease from $5.5 million or $0.34 per share in the comparable 2025 period. -- Net loss was $1.4 million or $0.04 per share, a 74% decrease from $5.5 million or $0.34 per share in the comparable 2025 period. Operating Loss -- Loss from operations increased to $4.7 million from $3.8 million in the prior year quarter, primarily due to expenses related to targeted strategic initiatives and pipeline expansion. -- Loss from operations increased to $4.7 million from $3.8 million in the prior year quarter, primarily due to expenses related to targeted strategic initiatives and pipeline expansion. Research and Development Expense -- R&D expense rose to $1.3 million from $0.8 million year over year. -- R&D expense rose to $1.3 million from $0.8 million year over year. General and Administrative Expense -- G&A expense, including selling costs, increased to $3.8 million from $2.9 million year over year. -- G&A expense, including selling costs, increased to $3.8 million from $2.9 million year over year. KETAFREE Regulatory Progress -- Jonathan Javitt issued "a labeling letter requesting only minor formatting changes and a positive disciplined review letter on ...
Joe_Potato/iStock Editorial via Getty Images Phillips 66 ( PSX ) is raised while refining peer HF Sinclair ( DINO ) is cut at Mizuho, where analyst Nitin Kumar forecasts the impact of the Iran crisis on global oil prices and refining cracks will be prolonged relative to Nymex, while the brokerage's natural gas price outlook remains relatively unchanged despite recent weakness. Kunar does not expec...
Joe_Potato/iStock Editorial via Getty Images Phillips 66 ( PSX ) is raised while refining peer HF Sinclair ( DINO ) is cut at Mizuho, where analyst Nitin Kumar forecasts the impact of the Iran crisis on global oil prices and refining cracks will be prolonged relative to Nymex, while the brokerage's natural gas price outlook remains relatively unchanged despite recent weakness. Kunar does not expect a normalization of crude supply until Q1 2027, even if a peace deal isreached by the end of June, as unprecedented inventory draws suggest a ~2.7M bbl/day undersupply in 2026 compared to an 800K bbl/day oversupply forecast prior to the war, adding that oil markets may only balance to midcycle ~$75/bbl Brent by year-end 2027. Among specific stocks, Phillips 66 ( PSX ) upgraded to Outperform from Neutral with a $212 price target, raised from $170, with Kumar anticipating a higher upside compared to other large-cap refining peers due to "improving refining operations, strong execution of strategic initiatives, and greater leverage to rising refining and chemicals margins." HF Sinclair ( DINO ) downgraded to Neutral from Outperform even as the price target is raised to $79 from $67, as the analyst sees "lower upside to our revised target that reflects the momentum on Refining reliability and costs, as well as the integration of Lubricants," adding that recent management changes raise uncertainty around the company's strategic direction. Gulfport Energy ( GPOR ) upgraded to Outperform from Neutral with a $252 PT, as Kumar expects incoming CEO Nick Dell'Osso to help raise the profile of the stock "specifically on positioning relative to secular trends in natural gas markets." Par Pacific ( PARR ) also upgraded to Outperform from Neutral with a $79 PT, anticipating a large upside in the stock on "strong recent results, a favorable distillate-driven margin backdrop, and optionality from SRE-related benefits." Kosmos Energy ( KOS ) cut to Underperform from Neutral with a $3 PT, se...
Key Points Mesa Laboratories fell after reporting its Q4 fiscal 2026 results. Sales and earnings came in below Wall Street's expected earnings, but the business did report strong growth for adjusted operating income. 10 stocks we like better than Mesa Laboratories › Mesa Laboratories (NASDAQ: MLAB) stock is getting crushed in Wednesday's trading. The life-science technologies company's share price...
Key Points Mesa Laboratories fell after reporting its Q4 fiscal 2026 results. Sales and earnings came in below Wall Street's expected earnings, but the business did report strong growth for adjusted operating income. 10 stocks we like better than Mesa Laboratories › Mesa Laboratories (NASDAQ: MLAB) stock is getting crushed in Wednesday's trading. The life-science technologies company's share price was down 19.5% as of 3:30 p.m. ET. Before the market opened this morning, Mesa Labs published results for the fourth quarter of its 2026 fiscal year -- a reporting period that ended March 31. While the company posted a significant beat for non-GAAP (adjusted) operating in the period, sales fell short of Wall Street's expectations. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Operating income growth hasn't been enough to stop big sell-offs Mesa Labs recorded a loss of $0.75 per share on sales of $63.72 million in fiscal Q4. Performance in the period saw revenue fall roughly $1.48 million short of the average Wall Street analyst target. On the other hand, the company did see strong growth for adjusted operating income. Mesa posted adjusted operating income per share of $3.30 last quarter, beating the average Wall Street analyst estimate by $1.76. Performance in the quarter marked a significant improvement over the company's adjusted operating income per share of $2.25 in the prior-year period. What's next for Mesa Labs? Mesa president and CEO Siddhartha Kadia is still conducting an internal review of the business and expects to be able to deliver full-year guidance with the company's fiscal Q2 report. The company says that it has seen some loosening in export controls for Peptide systems over the last month, and management sees further room for improvement when it comes to supporting growth in the produ...